Pirenzepine exhibits anti-prostate cancer activity and enhances checkpoint inhibitor-based immunotherapy by targeting STING
Abstract Purpose Therapeutic options targeting programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved for use in human malignancies, showing clinical benefits. Nonetheless, a significant number of patients, particularly those with prostate cancer (PCa), show...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2025-12-01
|
| coleção: | European Journal of Medical Research |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s40001-025-03520-4 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|